Human Dendritic Cells Synergistically Activated by FVIII Plus LPS Induce Activation of Autologous CD4+ T Cells
Lilija Miller
1
Section 3/1 “Product Testing of Biomedicines,” Paul-Ehrlich-Institut, Langen, Germany
,
Eva Ringler
1
Section 3/1 “Product Testing of Biomedicines,” Paul-Ehrlich-Institut, Langen, Germany
,
Klaus Maximilian Kistner
1
Section 3/1 “Product Testing of Biomedicines,” Paul-Ehrlich-Institut, Langen, Germany
,
Zoe Waibler
1
Section 3/1 “Product Testing of Biomedicines,” Paul-Ehrlich-Institut, Langen, Germany
,
on behalf of the ABIRISK Consortium› Author AffiliationsFunding Partially, the research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no [115303], resources of which are composed of financial contribution from the European Union's Seventh Framework Program (FP7/2007–2013) and EFPIA companies' in kind contribution.
The most severe side effect in haemophilia A (HA) treatment is the development of anti-factor VIII antibodies, also called inhibitors. Why inhibitors develop in a proportion of treated HA patients and how this can be prevented remains largely unanswered. Among numerous theories, the presence of immunological danger signals, associated with events such as surgery or infection, has been proposed to play a role. In this study, we demonstrate that human dendritic cells (DC) synergistically activated by a combination of factor VIII (FVIII) concentrate plus the bacterial danger signal lipopolysaccharide (LPS) induce a significantly stronger activation of autologous CD4+ T cells than DC pretreated with FVIII or LPS alone. The observed T cell activation is dependent on antigen processing, presentation on MHC class II molecules and costimulation via CD86. Of note, FVIII plus LPS pretreated DC predominantly induce the activation of memory T cells and a minor proportion of naive T cells. Collectively, our data support a model in which immunological danger signals plus FVIII concentrates synergistically increase human CD4+ T cell responses to FVIII protein.
Keywords
anti-FVIII immune response -
lipopolysaccharide -
T cells -
danger signal -
inhibitors
Authors' Contributions
L.M. performed experiments, collected, analysed and interpreted the data, generated figures and wrote the article; E.R. and K.M.K. performed experiments; Z.W. designed experiments, interpreted the data and wrote the article.
2
Gouw SC,
van den Berg HM,
Oldenburg J.
, et al.
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 2012; 119 (12) 2922-2934
4
Eckhardt CL,
van Velzen AS,
Peters M.
, et al; INSIGHT Study Group. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood 2013; 122 (11) 1954-1962
5
Hu G-L,
Okita DK,
Diethelm-Okita BM,
Conti-Fine BM.
Recognition of coagulation factor VIII by CD4+ T cells of healthy humans. J Thromb Haemost 2003; 1 (10) 2159-2166
6
Whelan SFJ,
Hofbauer CJ,
Horling FM.
, et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood 2013; 121 (06) 1039-1048
7
Algiman M,
Dietrich G,
Nydegger UE,
Boieldieu D,
Sultan Y,
Kazatchkine MD.
Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc Natl Acad Sci U S A 1992; 89 (09) 3795-3799
8
Miller L,
Weissmüller S,
Ringler E.
, et al; ABIRISK consortium. Danger signal-dependent activation of human dendritic cells by plasma-derived factor VIII products. Thromb Haemost 2015; 114 (02) 268-276
9
Gouw SC,
van der Bom JG,
Marijke van den Berg H.
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109 (11) 4648-4654
11
Gouw SC,
van den Berg HM.
The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Hemost 2009; 35 (08) 723-734
12
Yoshimori T,
Yamamoto A,
Moriyama Y,
Futai M,
Tashiro Y.
Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol Chem 1991; 266 (26) 17707-17712
13
Mayer S,
Laumer M,
Mackensen A,
Andreesen R,
Krause SW.
Analysis of the immune response against tetanus toxoid: enumeration of specific T helper cells by the Elispot assay. Immunobiology 2002; 205 (03) 282-289
16
Koehler NKU,
Genain CP,
Giesser B,
Hauser SL.
The human T cell response to myelin oligodendrocyte glycoprotein: a multiple sclerosis family-based study. J Immunol 2002; 168 (11) 5920-5927
17
Reding MT,
Wu H,
Krampf M.
, et al. Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects. Thromb Haemost 2000; 84 (04) 643-652
18
Moreau A,
Lacroix-Desmazes S,
Stieltjes N.
, et al. Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG. Blood 2000; 95 (11) 3435-3441
20
Bischoff SC,
Barbara G,
Buurman W.
, et al. Intestinal permeability--a new target for disease prevention and therapy. BMC Gastroenterol 2014; 14: 189